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S-phase entry upon ectopic expression of G1 cyclin-dependent
kinases in the absence of retinoblastoma protein phosphorylation
Xiaohong Leng*, Lisa Connell-Crowley*, David Goodrich† and J. Wade Harper*
In mammalian cells, the retinoblastoma protein (Rb) is
thought to negatively regulate progression through the
G1 phase of the cell cycle by its association with the
transcription factor E2F [1–3]. Rb–E2F complexes
suppress transcription of genes required for DNA
synthesis ([4], reviewed in [3,5]), and the prevailing view
is that phosphorylation of Rb by complexes of cyclin-
dependent kinases (Cdks) and their regulatory cyclin
subunits, and the subsequent release of active E2F, is
required for S-phase entry [1–3]. This view is based, in
part, on the fact that ectopic expression of cyclin–Cdks
leads to Rb phosphorylation and that this modification
correlates with S-phase entry [6–8]. In Drosophila,
however, cyclin E expression can bypass a requirement
for E2F, suggesting that cyclins may activate replication
independently of the Rb/E2F pathway [9]. We sought to
examine whether Rb phosphorylation is a prerequisite
for S-phase entry in Rb-deficient SAOS-2 osteosarcoma
cells, using a commonly used cotransfection assay
[6–8,10]. We find that a G1 arrest in SAOS-2 cells
mediated by an Rb mutant lacking all 14 consensus Cdk
phosphorylation sites is bypassed by coexpressing G1-
specific E-type or D-type cyclin–Cdk complexes, and
that injection of purified cyclin–Cdks during G1
accelerates S-phase entry. Our results indicate that Rb
phosphorylation is not essential for S-phase entry when
G1 cyclin–Cdks are overexpressed, and that other
substrates of these kinases can be rate-limiting for the
G1 to S-phase transition. These data also reveal that
the SAOS-2 cotransfection assay is complicated by Rb-
independent effects of the coexpressed Cdks. 
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Results and discussion
An Rb mutant (Rb∆Cdk) was generated containing serine
and threonine to alanine substitutions at all 14 consensus
Cdk phosphorylation sites (Figure 1a). Like wild-type Rb,
Rb∆Cdk associates with E2F when coexpressed in insect
cells (Figure 1b) and binds avidly to a peptide affinity
column in which the peptide, derived from the papilloma
E7 oncoprotein, contains the motif Leu–X–Cys–X–Glu, in
which X is any amino acid (Figure 1d), indicating that
both the E2F-binding domain and the large pocket of Rb
are functional in this mutant. This mutant would, there-
fore, be expected to interact with cellular targets, thereby
blocking S-phase entry, but would not be expected to be
regulated by Cdk-mediated phosphorylation. When co-
expressed with cyclin E–Cdk2 or cyclin D1–Cdk4,
Rb∆Cdk comigrated with the hypophosphorylated form of
Rb, whereas wild-type Rb underwent a characteristic
decrease in electrophoretic mobility associated with its
phosphorylation (Figure 1c). Consistent with the inability
of Rb∆Cdk to be phosphorylated by Cdks, neither
cyclin E–Cdk2 nor cyclin D1–Cdk4 phosphorylated
Rb∆Cdk in vitro under conditions in which Rb is exten-
sively phosphorylated on a subset of in vivo phosphoryla-
tion sites (Figure 1d and [11]). 
We then tested Rb∆Cdk in a SAOS-2 cotransfection assay
that has previously been used to establish the roles of Rb
and Cdks in cell cycle entry [6–8,10]. As expected, expres-
sion of Rb∆Cdk in SAOS-2 cells led to a G1 arrest, as
assessed by flow cytometry (Figure 2), and also produced
the ‘flat cell’ phenotype characteristic of Rb expression in
this cell line (data not shown). Surprisingly, however,
cotransfection of Rb∆Cdk with plasmids expressing
cyclin E–Cdk2, cyclin D1–Cdk4, or cyclin E alone
resulted in a substantial increase in the S-phase popula-
tion at the expense of G1 cells (Figure 2 and data not
shown). For example, cotransfection of Rb∆Cdk with
cyclin E–Cdk2 led to a 21–41% increase in the fraction of
S-phase cells in three independent experiments, similar to
the 25–44% increase observed with Rb (Figure 2).
Although cyclin D1–Cdk4 was somewhat less effective at
overriding Rb in this assay, the increase in S-phase cells
was comparable for both Rb and Rb∆Cdk (10–26%).
Expression of Cdk complexes alone also increased the
percentage of S-phase cells compared to cells transfected
with empty vector (Figure 2). 
Similar results were obtained in a pulse bromodeoxyuridine
(BrdU) incorporation assay that examines DNA synthesis
directly in Rb-expressing cells (Figure 3). As expected, less
than 1% of cells positive for Rb or Rb∆Cdk became labeled
with BrdU in the absence of cyclin expression. Over 80% of
Rb-positive cells were BrdU-positive, however, when Rb
was coexpressed with cyclin E–Cdk2 or a mixture of
cyclin E–Cdk2 and cyclin D1–Cdk4, regardless of whether
or not the Rb they expressed had Cdk phosphorylation
sites (Figure 3). Cyclin D1–Cdk4 (Figure 3b) and
cyclin D3–Cdk4 (data not shown) were also capable of
inducing S phase in cells expressing Rb∆Cdk, albeit with a
lower efficiency than cyclin E–Cdk2. However, neither
cyclin D1 alone nor cyclin D1 together with either a
kinase-inactive Cdk4 mutant (D158N) [10] or Cdk2 effec-
tively overcame arrest by Rb or Rb∆Cdk in this assay
(Figure 3 and data not shown). Cyclin D1 does not effi-
ciently activate Cdk2 as an Rb kinase [8].
These data suggested that expression of cyclin–Cdks can
effect replication independently of Rb phosphorylation.
Whereas both cyclin E and cyclin D1 have been shown to
accelerate G1 progression in Rb-positive fibroblasts
[12–14], and cyclin E–Cdk2 is required for DNA replica-
tion in vitro [15], the question of whether these cyclins
can accelerate S-phase entry independently of Rb has not
been addressed. To examine this question, active
cyclin–Cdk complexes were injected into SAOS-2 cells
during early or mid G1, and BrdU incorporation was used
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(a) Cyclin–Cdks override G1 arrest by Rb∆Cdk. SAOS-2 cells were
transfected using calcium phosphate and 1 µg each of either empty
vector (pCMV) or vector encoding Rb (pCMV–Rb) or Rb∆Cdk
(pCMV–Rb∆Cdk), and vectors encoding cyclin E and Cdk2 (E/K2)
and/or cyclin D1 and Cdk4 (D1/K4), as well as 0.5µg of pCMV–CD20,
which encodes CD20, a cell surface marker used to identify transfected
cells [10], in a total of 10 mg DNA. All proteins were expressed under
the control of the cytomegalovirus (CMV) promoter and constant levels
of CMV-promoter-containing DNA were maintained. The DNA content
of 1000–3000 CD20-positive cells was determined by flow cytometry
48 h later, as described [10]. Of three experiments performed, (a)
histograms from the second experiment and (b) the DNA content of
transfected cells from all three experiments are shown.
Figure 1
(a) Rb structure showing consensus Cdk
phosphorylation sites (S/T), sites of
phosphorylation by E-type and D-type
cyclin–Cdks in vitro [11] (asterisks), and
phosphorylation sites mutated to alanine (A)
[11] in Rb∆Cdk. Encircled serines are within
Ser–Pro sequences that do not fit the Cdk
consensus (Ser–Pro–X–Arg/Lys, in which X is
any amino acid). (b) Rb∆Cdk associates with
E2F in insect cells. Insect cells infected with
the indicated baculovirus combinations were
lysed as described [11]. Complexes of Rb and
a fusion protein of glutathione-S-transferase
and E2F (GST–E2F) were purified using
glutathione (GSH) Sepharose, and proteins
were separated by gel electrophoresis before
immunoblotting with anti-Rb antibodies (Santa
Cruz SC-050). (c) Rb, but not Rb∆Cdk, is
converted to slower migrating phosphorylated
forms (Rb-P) upon coexpression with
cyclin–Cdks in SAOS-2 cells (see Figure 2
legend for transfection methods). Cell lysates
were immunoblotted using anti-Rb antibodies
(Pharmingen 10041A). (d) Rb∆Cdk is not
phosphorylated in vitro by cyclin–Cdks. Rb and
Rb∆Cdk were expressed in insect cells and
purified by affinity chromatography on a resin of
Sepharose covalently joined to E7 peptide
(Thr–Asp–Leu–Tyr–Cys–Tyr–Glu–Gln–Leu–A
sn) and eluted with unbuffered 50 mM Na2CO3
containing 150 mM NaCl and 1 mM DTT
before neutralization with 1 M HEPES, pH 7.0
[19]. For Rb phosphorylation, Rb proteins
(500 nM) were treated with 20 nM
cyclin D1–Cdk4 (D1/K4) or cyclin E–Cdk2
(E/K2), as described [11]. Rb was then purified
from reaction mixtures by immunoprecipitation
prior to gel electrophoresis. Replica gels were
either immunoblotted to verify Rb levels (αRb)
or subjected to autoradiography to visualize
phosphorylation ([32P]Rb).
A B C
Rb
A A A AA AA
S S S SS S S S S ST T TT T T
(a)
(c) Rb∆Cdk
D1/K4
D1/K4
– –
–
– –
–+
+
+
+
+
+
– –+
+
E/K2
E/K2
** * * * * * *
[32P]Rb
αRb
Rb RbRb∆Cdk Rb∆Cdk
 Rb
Rb-P 
A
αRb
GST–E2F    
           Rb
    Rb∆Cdk
+ + +
+ +
+ +
– –
– ––
– – –
GSH Sepharose
(b)
(d)
to measure the fraction of cells entering S phase over
time (Figure 4). When injected with cyclin E–Cdk2 10 h
after release from mitosis, 60% of the cells were in S
phase 15 h after release, compared with less than 10% in
mock-injected cells (Figure 4a). Mock-injected cells
reached 60% BrdU incorporation 25–27 h after release,
indicating a dramatic 10–12 h acceleration of S-phase
entry by cyclin E–Cdk2. When injected with
cyclin E–Cdk2 4 h after release, over 85% of the cells
were BrdU-positive at 13 h, intimating that the earlier
cyclin E–Cdk2 is present in G1, the earlier cells will initi-
ate replication (Figure 4b). Interestingly, cyclin D1–Cdk4
can also accelerate S-phase entry, albeit less efficiently
than cyclin E–Cdk2; 17 h after release from mitosis, less
than 2% of mock-injected cells were BrdU positive,
whereas over 60% of the cyclin D1–Cdk4-injected cells
had initiated replication (Figure 4b). Thus, G1
cyclin–Cdk complexes can affect the timing of and/or
commitment to S phase, independent of Rb.
Consistent with our studies, Lukas et al. [16] recently
reported that cyclin E can bypass an Rb mutant lacking
Cdk phosphorylation sites. Importantly, their studies also
showed that transcription from an E2F promoter–reporter
plasmid is still repressed by the Rb mutant while cells are
entering S phase as a result of cyclin E expression. Taken
together with our work, these results indicate that the pre-
vailing view of how Cdks regulate the G1 to S phase tran-
sition is incomplete. Although Rb phosphorylation and
release of active E2F are induced by cyclin–Cdk cotrans-
fection ([6–8,12] and Figure 1), these kinases can simulta-
neously promote cell cycle progression independently of
Rb/E2F, presumably by acting upon downstream targets
that are rate-limiting for S phase. Further studies are
required to determine whether the ability of ectopic
cyclin E to bypass the Rb–E2F pathway simply reflects
the fact that Rb normally represses cyclin E expression
while not significantly affecting other E2F-regulated
genes [17,18]. 
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Figure 3
(a) Cells cotransfected to express the
indicated proteins, as described in Figure 2,
were incubated for 6 h with 10 µM BrdU to
label S-phase cells before
immunofluorescence. BrdU incorporation was
visualized using anti-BrdU antibodies (Becton-
Dickinson; green) and Rb expression using
anti-Rb antibodies (red). Nuclei were
identified using 4,6-diamidino-2-phenylindole
(DAPI; blue). (b) Summary of three
experiments depicting the proportion of Rb-
expressing cells that incorporated BrdU. For
each experiment, about 100 Rb-positive cells
were counted.
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Figure 4
Injection of active cyclin–Cdk complexes
accelerates S-phase entry. SAOS-2 cells
(about 100 per time point) were injected with
either biotinylated rabbit immunoglobulin G
(IgG) or a mixture of IgG and the indicated
kinase (at 10 µM) (a) 10 h or (b) 4 h after
release from a nocodazole block [11], and
10 µM BrdU was added. As a kinase source, a
fusion protein of glutathione-S-transferase
(GST) and cyclin E, complexed to Cdk2
(GST–E/K2), and a GST–Cdk4 fusion protein
complexed to cyclin D1 (D1/GST–K4) were
purified from insect cells [11] and exchanged
into injection buffer [50 mM Tris-HCl (pH 7.5),
150 mM NaCl] using a Centricon-30. Cells
were processed at the indicated times for
immunofluorescence to detect BrdU-positive,
IgG-positive cells [11]. (c) Gel electrophoresis
of the kinases used for injection; insect cell
GST protein is marked with an asterisk.
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Our results also indicate that the Rb/cyclin SAOS-2
cotransfection assay is confounded by Rb-independent
effects of cyclin–Cdks on DNA replication. We have
recently presented an alternative assay for examining Rb
regulation in which Rb modified in vitro by Cdks is
assayed for growth suppression by microinjection in the
absence of exogenous cyclin–Cdks [11]. In this assay,
mutation of a single critical cyclin D1–Cdk4 phosphoryla-
tion site in Rb (Ser795→Ala) blocks the ability of this
kinase to inactivate Rb’s growth suppressive function
upon phosphorylation of Rb in vitro, indicating that this
Rb mutant acts in a dominant fashion when Cdks are not
introduced into the cell [11]. In contrast, we have shown
here that when cyclin D1–Cdk4 is introduced into cells,
growth arrest mediated by Rb lacking all its
cyclin D1–Cdk4 phosphorylation sites is bypassed
(Figures 2 and 3). We also found previously that hyper-
phosphorylation of Rb in vitro by cyclin E–Cdk2 is not
sufficient to inactivate Rb’s G1 arrest activity [11] but, as
for cotransfection, introduction of Rb and cyclin E–Cdk2
into cells by coinjection leads to S-phase entry (L.C-C.,
J.W.H. and D.G., unpublished observations). Thus, intro-
duction of cyclin–Cdks into cells can affect DNA replica-
tion independently of upstream regulatory pathways.
Surprisingly, we found that cyclin D1–Cdk4, but not
cyclin D1 alone, can also bypass a G1 arrest mediated by
Rb∆Cdk. Moreover, we also found that cyclin D1–Cdk4
can accelerate S-phase entry in the absence of Rb, indicat-
ing that this kinase can affect replication independently of
its ability to phosphorylate Rb. Lukas et al. [16] have also
shown that cyclin D1 alone is not sufficient to bypass
Rb∆Cdk but did not address whether cyclin D1–Cdk4 can
bypass this ‘non-phosphorylatable’ Rb mutant. It is
unlikely that the ability of cyclin D1–Cdk4 to bypass
Rb∆Cdk depends upon a physical association of cyclin D1
with Rb [7,8], as neither cyclin D1 alone nor cyclin D1
associated with kinase-defective Cdk4 can efficiently
bypass Rb-mediated growth arrest. The latter finding also
suggests that Cdk4 activity is required, which would argue
against Cdk-inhibitor sequestration by cyclin D1–Cdk4
being involved in Rb∆Cdk bypass, but does not absolutely
rule it out. Whereas cyclin D1 is not required for S-phase
entry in cells lacking Rb (reviewed in [1,2]), it is possible
that cyclin D1–Cdk4 shares substrates with
cyclin E–Cdk2, making cyclin D1–Cdk4 expendable for
S-phase entry in Rb-deficient cells. In this case,
cyclin D1–Cdk4 may induce S phase using pathways that
are normally operative in the cell, but which are redun-
dant in the presence of active cyclin E–Cdk2. Alterna-
tively, the effects of overexpressed cyclin D1–Cdk4 may
reflect a non-physiological loss of specificity of the kinase
activity when expressed at high levels. The identification
of downstream targets for these kinases is required to
resolve this issue. Nevertheless, our results suggest the
possibility that overexpression of cyclin D may contribute
to cell cycle progression and transformation [2] through
both Rb-dependent and Rb-independent pathways.
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